Report Categories
View AllRecent Articles
View All
VIST Vista shares gain 229 percent on positive investor reception of its Q1 2026 earnings
The real story behind CareDx CDNA earnings numbers Q1 2026 Better Than Expected
What Recursion Pharmaceuticals RXRX doing to improve profitability Q1 2026 Earnings Beat Estimates
What Arbutus ABUS subscription metrics reveal about retention Arbutus notches 44 EPS beat with narrower than expected loss